Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a “real-life” cohort of 65 chronic phase C...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neoplasia
Main Authors: Latagliata, Roberto, Stagno, Fabio, Annunziata, Mario, Abruzzese, Elisabetta, Iurlo, Alessandra, Guarini, Attilio, Fava, Carmen, Gozzini, Antonella, Bonifacio, Massimiliano, Sorà, Federica, Leonetti Crescenzi, Sabrina, Bocchia, Monica, Crugnola, Monica, Castagnetti, Fausto, Capodanno, Isabella, Galimberti, Sara, Feo, Costanzo, Porrini, Raffaele, Pregno, Patrizia, Rizzo, Manuela, Antolino, Agostino, Mauro, Endri, Sgherza, Nicola, Luciano, Luigiana, Tiribelli, Mario, Russo Rossi, Antonella, Trawinska, Malgorzata, Vigneri, Paolo, Breccia, Massimo, Rosti, Gianantonio, Alimena, Giuliana
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2016
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5031865/
https://ncbi.nlm.nih.gov/pubmed/27659013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2016.07.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados